Nav: Home

Portable biological factories create pharmaceuticals

October 03, 2016

Pellets made from freeze-dried molecular components make it possible to "just add water" to create diverse compounds without the need for refrigeration. This portable and inexpensive platform, intended to help those far away from hospitals or even astronauts on the space station, could allow for the creation of pharmaceuticals, specialized therapies, and experimental biomolecules. The technology, developed by Harvard and MIT researchers, is presented September 22 in Cell.

"I think this opens up possibilities of creating a biotech equivalent of the chemistry kits many of us grew up with that consisted of powders and chemicals," says senior author James Collins, who runs a lab at the Wyss Institute for Biologically Inspired Engineering. "Now, we show that you can actually have freeze-dried DNA components and other biomolecules that can be used in an easy, low-resource way to explore the power of our technology."

Rather than freeze-drying the end molecules and re-hydrating them, the Collins Lab freeze-dries the molecular machinery for transcription and translation, which are then made into reaction pellets. After water is added to rehydrate the pellets, the molecular machinery gets to work creating the desired end molecule.

The technology is applicable in a wide variety of applications. For example, since antibodies are increasingly being used to treat microbial infections and diseases ranging from cancer to immune disorders, the researchers used their system to create a portable, modular toolbox for making designer antibodies against a variety of disease-relevant targets. This included one that could neutralize C. difficile bacteria, which cause fatal infections in people, and another that was able to target and kill breast cancer cells.

The researchers also explored on-site vaccine production by testing the ability of the pellets to synthesize a vaccine against diphtheria. The vaccine is sensitive to both heating and freezing, making its storage and global distribution challenging, and the ability to rapidly synthesize it on site would thus be an important advance. The scientists found that the pellet-synthesized vaccine was able to elicit a protective response in mice.

"We showed that you could get an appropriate biological response," says Collins. "We're not developing novel vaccines, but we're showing that if we can encode the antigens in DNA, then we can harness that ability and have the vaccines in an easy-to-ship and -store format."

This new approach to biomolecular manufacturing costs an average of $0.03 per microliter, making it about 10 times less expensive than its commercial counterpart, although the exact cost can vary depending on the molecules being manufactured. The reaction pellets can be transported at room temperature and may provide a solution for problems doctors and scientists may face when they lack adequate refrigeration facilities. Additionally, because, for most uses, the pellets have simple instructions for use--"just add water"--very little training would be required for therapeutic use.

Collins and his team are optimistic about other potential uses of this technology, including futuristic applications for long-term medical treatment during space travel. Although Collins admits that scalability may be an issue with certain molecules that are not immediately amenable to the freeze-drying process, his team is discussing the next steps they can take with this technology.

In addition to expanding the process to work with more complex molecules, his lab is looking to adapt the platform so that it can be used in field work, to extend the platform to educational applications, and to determine how the technology could be used for additional small-molecule production.
-end-
The work was supported by the Wyss Institute for Biologically Inspired Engineering, the Ragon Institute, the Paul G. Allen Frontiers Group, and the Defense Threat Reduction Agency.

Cell, Pardee, Slomovic, Nguyen, and Lee et al: "Portable, on-demand biomolecular manufacturing" http://www.cell.com/cell/fulltext/S0092-8674(16)31246-6

Cell (@CellCellPress), the flagship journal of Cell Press, is a bimonthly journal that publishes findings of unusual significance in any area of experimental biology, including but not limited to cell biology, molecular biology, neuroscience, immunology, virology and microbiology, cancer, human genetics, systems biology, signaling, and disease mechanisms and therapeutics. Visit http://www.cell.com/cell. To receive Cell Press media alerts, contact press@cell.com.

Cell Press

Related Vaccine Articles:

Exposing vaccine hesitant to real-life pain of diseases makes them more pro-vaccine
New research from Brigham Young University professors finds there is a better way to help increase support for vaccinations: Expose people to the pain and suffering caused by vaccine-preventable diseases instead of trying to combat people with vaccine facts.
Lifetime flu vaccine?
Another year, another flu vaccine because so far scientists haven't managed to make a vaccine that protects against all strains of flu.
On the horizon: An acne vaccine
A new study published in the Journal of Investigative Dermatology reports important steps that have been taken towards the development of an acne vaccine.
Study examines first birth cohort to receive HPV vaccine: The vaccine works
Girls in the first birth cohort to be offered and receive the HPV vaccine showed a lower degree of dysplasia which may eventually lead to cervical cancer than a birth cohort from 1983.
False beliefs about MMR vaccine found to influence acceptance of Zika vaccine
People's willingness to use a Zika vaccine, once it's available, will be influenced by how they weigh the risks associated with the disease and the vaccine, but also by their misconceptions about other vaccines.
Would you pay for an Ebola vaccine? Most say yes.
George Mason University researchers conducted a study during the height of the 2014-2016 Ebola epidemic and found that a majority of participants (59.7 percent) would pay at least $1 for a vaccine.
How well will the flu vaccine work this winter?
Scientists from UTMB and Biomed Protection predicted which H3N2 variants would become 'vaccine resistant', and this prediction has been confirmed during the 2017 Australian flu season.
Virus-like particle vaccine protects against RSV vaccine-enhanced respiratory disease, study finds
Researchers have discovered that a virus-like particle vaccine can prime the body's immune response and prevent the severe respiratory disease that results when patients given an early form of a vaccine for respiratory syncytial virus (RSV) are exposed to RSV, according to a study led by Georgia State University.
Flu vaccine rates for kids may drop when the nasal spray vaccine is unavailable
Influenza vaccination rates in children may have decreased for the 2016-17 influenza season because of a recommendation by the Centers for Disease Control and Prevention that the nasal spray version of the vaccine not be used, according to Penn State College of Medicine researchers.
Development of a novel vaccine for Zika
Research presented by Farshad Guirakhoo, Ph.D., Chief Scientific Officer, GeoVax, Inc., at the ASM Microbe 2017 meeting showed a new Zika virus vaccine that gives 100 percent protection in mice.
More Vaccine News and Vaccine Current Events

Top Science Podcasts

We have hand picked the top science podcasts of 2019.
Now Playing: TED Radio Hour

Accessing Better Health
Essential health care is a right, not a privilege ... or is it? This hour, TED speakers explore how we can give everyone access to a healthier way of life, despite who you are or where you live. Guests include physician Raj Panjabi, former NYC health commissioner Mary Bassett, researcher Michael Hendryx, and neuroscientist Rachel Wurzman.
Now Playing: Science for the People

#544 Prosperity Without Growth
The societies we live in are organised around growth, objects, and driving forward a constantly expanding economy as benchmarks of success and prosperity. But this growing consumption at all costs is at odds with our understanding of what our planet can support. How do we lower the environmental impact of economic activity? How do we redefine success and prosperity separate from GDP, which politicians and governments have focused on for decades? We speak with ecological economist Tim Jackson, Professor of Sustainable Development at the University of Surrey, Director of the Centre for the Understanding of Sustainable Propserity, and author of...
Now Playing: Radiolab

An Announcement from Radiolab